SMTL ID : 4anq.1

Structure of G1269A Mutant Anaplastic Lymphoma Kinase in Complex with Crizotinib

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 1.76 Å

Oligo State

monomer

Ligands

1 x VGH: 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-amine(Non-covalent)

VGH.1: 15 residues within 4Å: Chain A: L.53, V.61, A.79, L.127, E.128, L.129, M.130, A.131, G.132, G.133, R.184, N.185, L.187, A.200, D.201 6 PLIP interactions: 6 interactions with chain A Hydrophobic interactions: A:L.53, A:L.127, A:L.187 Hydrogen bonds: A:E.128, A:M.130 Water bridges: A:D.134

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Huang, Q. et al., Design of Potent and Selective Inhibitors to Overcome Clinical Anaplastic Lymphoma Kinase Mutations Resistant to Crizotinib. J.Med.Chem. (2014)

Release Date

2013-03-27

Peptides

ALK TYROSINE KINASE RECEPTOR: A

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

ALK TYROSINE KINASE RECEPTOR

Related Entries With Identical Sequence